US20190216904A1 - Methods and pharmaceuticals for treatment of viral infections of the eye - Google Patents
Methods and pharmaceuticals for treatment of viral infections of the eye Download PDFInfo
- Publication number
- US20190216904A1 US20190216904A1 US16/368,330 US201916368330A US2019216904A1 US 20190216904 A1 US20190216904 A1 US 20190216904A1 US 201916368330 A US201916368330 A US 201916368330A US 2019216904 A1 US2019216904 A1 US 2019216904A1
- Authority
- US
- United States
- Prior art keywords
- eye
- ribonuclease
- ranpirnase
- pharmaceutical composition
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 24
- 230000009385 viral infection Effects 0.000 title abstract description 18
- 208000036142 Viral infection Diseases 0.000 title abstract description 17
- 238000011282 treatment Methods 0.000 title description 11
- 239000003814 drug Substances 0.000 title description 3
- 108010061338 ranpirnase Proteins 0.000 claims abstract description 59
- 229950007649 ranpirnase Drugs 0.000 claims abstract description 59
- 108010083644 Ribonucleases Proteins 0.000 claims abstract description 58
- 102000006382 Ribonucleases Human genes 0.000 claims abstract description 58
- 101710176912 Amphinase-2 Proteins 0.000 claims abstract description 17
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 25
- 238000011156 evaluation Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 231100000344 non-irritating Toxicity 0.000 claims description 10
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 7
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 7
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- 208000007514 Herpes zoster Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 5
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 5
- 206010023332 keratitis Diseases 0.000 claims description 5
- 201000004709 chorioretinitis Diseases 0.000 claims description 4
- 206010010755 Conjunctivitis viral Diseases 0.000 claims description 3
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims description 3
- 239000000412 dendrimer Substances 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000000017 hydrogel Substances 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000004530 micro-emulsion Substances 0.000 claims description 3
- 239000007908 nanoemulsion Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000006070 nanosuspension Substances 0.000 claims description 3
- 239000002353 niosome Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 206010019972 Herpes viral infections Diseases 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000700586 Herpesviridae Species 0.000 abstract description 10
- 241000701242 Adenoviridae Species 0.000 abstract description 8
- 108700010877 adenoviridae proteins Proteins 0.000 abstract description 7
- 210000001508 eye Anatomy 0.000 description 41
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 231100000635 Draize test Toxicity 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 208000003809 Herpes Zoster Ophthalmicus Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 208000000222 Viral Eye Infections Diseases 0.000 description 3
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000006476 shipyard eye Diseases 0.000 description 3
- -1 '805 variant Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- WPVFJKSGQUFQAP-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropyl] 2-amino-3-methylbutanoate Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)C(N)C(C)C)C=N2 WPVFJKSGQUFQAP-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940124977 antiviral medication Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000269 corneal opacity Toxicity 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 208000013441 ocular lesion Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940093257 valacyclovir Drugs 0.000 description 2
- 230000004304 visual acuity Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710115432 Brain ribonuclease Proteins 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 206010056476 Corneal irritation Diseases 0.000 description 1
- 241000709734 Coxsackievirus A24 Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000057955 Eosinophil Cationic Human genes 0.000 description 1
- 101710191360 Eosinophil cationic protein Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000709716 Human enterovirus 70 Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000190534 Inkoo virus Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000700560 Molluscum contagiosum virus Species 0.000 description 1
- 101710118518 Non-secretory ribonuclease Proteins 0.000 description 1
- 102100034217 Non-secretory ribonuclease Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000270942 Rana pipiens Species 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002616 endonucleolytic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 231100001032 irritation of the eye Toxicity 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y02A50/382—
-
- Y02A50/385—
-
- Y02A50/393—
Definitions
- the invention relates to viral infections of the eye, and more particularly relates to methods and pharmaceuticals for treatment of viral infections of the eye.
- the invention relates to treatment of human eye infections caused by Herpesviridae viruses (including but not limited to Human cytomegalovirus, herpes zoster virus, and varicella zoster virus) and Adenoviridae viruses.
- Type 1 herpes simplex virus can cause conjunctivitis and keratitis
- Human cytomegalovirus can cause retinitis
- adenovirus types 8, 19, 29, and 37 can cause epidemic keratoconjunctivitis
- adenovirus types 3, 4, and 7 can cause pharyngoconjuctival fever.
- Herpes zoster virus (HZV) a member of the Herpesviridae family, can cause severe eye disease when affecting the trigeminal area.
- Herpes zoster ophthalmicus a severe form of acute herpes zoster, results from the reactivation of varicella zoster virus (VZV) (another member of the Herpesviridae family) in the trigeminal (fifth cranial) nerve. Any branch of the nerve may be affected, though the frontal branch within the first division of the trigeminal nerve is most commonly involved. This frontal branch innervates nearly all of the ocular and periocular structures. Herpes zoster ophthalmicus at this particular location can lead to blindness and requires a fast and effective therapeutic approach.
- VZV varicella zoster virus
- CMV Human cytomegalovirus
- CMV retinitis is one of the most common opportunistic infections in persons with AIDS or pharmacologically induced immunosuppression. Individuals with CMV retinitis typically exhibit a progressive decrease in visual acuity, which may progress to blindness. Long-term CMV treatment is necessary to prevent retinitis relapse.
- Immune reconstitution syndrome is reported in 16%-63% of HIV-infected patients with CMV retinitis following the initiation of HAART (Highly Active Antiretroviral Treatment).
- CMV IRIS may manifest as painless floaters, blurred vision, photopia, decreased visual acuity, or ocular pain.
- Some patients may develop macular edema leading to vision loss or proliferative vitreoretinopathy, spontaneous vitreal hemorrhage, and retinal detachment.
- Topical acyclovir must be applied frequently and causes irritation of the eye. Oral acyclovir causes significant adverse side effects.
- Other antiviral medications such as gancyclovir, valacyclovir and valgancyclovir are used to treat viral eye infections, and such treatments are also not entirely satisfactory.
- Gancyclovir is administered intravenously, and therefore cannot be used outside e.g. a hospital setting.
- Oral antiviral medications such as valacyclovir and valgancyclovir have disadvantages; they are known to cause fever, rash, diarrhea, and hematologic effects (e.g., neutropenia, anemia, thrombocytopenia).
- neutropenia may respond to lowering the dose or using drugs that stimulate the production of neutrophils by the bone marrow as granulocyte colony-stimulating factor [G-CSF], or granulocyte-macrophage colony-stimulating factor [GM-CSF].
- G-CSF granulocyte colony-stimulating factor
- GM-CSF granulocyte-macrophage colony-stimulating factor
- ranpirnase and other proteins that are highly homologous to it, are known to have antiviral activity, and to have activity against viruses in the Herpesviridae family (specifically including but not limited to Herpes simplex virus types 1 and 2 and Human cytomegalovirus) and also against type 2 adenovirus.
- proteins are known to be highly irritating to the eye due to an intense inflammatory response mediated by T-cells. For this reason, although ranpirnase and other related proteins have been investigated for use against various viral infections, they have not been investigated for use against viral infections of the eye.
- ranpirnase Despite the expectation that proteinaceous ranpirnase would cause irritation in the eye, irritation of topically applied ranpirnase in the eye was studied in a rabbit model. In this experiment, ranpirnase was demonstrated to be non-irritating as determined using the Globally Harmonized System of Classification Evaluation Criteria and the European Economic Community Ocular Evaluation Criteria. This was a remarkable result, because administration of a foreign protein to the eye can produce corneal irritation. As a result, ranpirnase and other proteins that are highly homologous to it are expected to be useful in treating viral infections of the human eye.
- FIG. 1 shows the scale used for scoring ocular lesions observed in a rabbit that has undergone a Draize test
- FIG. 2 shows the results of a Draize test in which a ranpirnase solution was applied to the right eye of three rabbits;
- FIG. 3 shows the results of the Draize test of FIG. 2 in which the left eye of each of the rabbits was untreated.
- FIG. 4 shows the European Economic Community Ocular Evaluation Criteria used to classify the ocular irritation caused by a test article in a Draize test.
- Ranpirnase is a proteinaceous enzymatically active ribonuclease (the word “ribonuclease” is frequently abbreviated as “RNase”) that is disclosed and claimed in U.S. Pat. No. 5,559,212.
- RNase ribonuclease
- U.S. Pat. Nos. 5,728,805, 6,239,257, 7,229,824 and 8,518,399 disclose three other proteinaceous enzymatically active ribonucleases that are highly homologous to ranpirnase:
- U.S. Pat. No. 8,518,399 discloses that ranpirnase, the '805 variant, and rAmphinase 2 have antiviral activity against Herpesviridae viruses, specifically including but not limited to Herpes simplex types 1 and 2 and Human cytomegalovirus. Based upon its similarities with these three enzymatically active ribonucleases, it is believed that Amphinase 2 will have these activities as well.
- ranpirnase has antiviral activity against a number of viruses, including type 2 adenovirus.
- viruses in the Adenoviridae family are very closely related and the demonstrated antiviral activity of ranpirnase against any one virus within the Adenoviridae family is strong evidence that ranpirnase will have the same anti-replication activity against all viruses within the Adenoviridae family.
- ranpirnase the '805 variant, Amphinase 2, and rAmphinase 2 have either been demonstrated to be active against type 1 Herpes simplex virus and viruses in the Adenoviridae family or would be expected to be so active. For this reason, a person of ordinary skill in the art would expect that all four of these proteinaceous enzymatically active ribonucleases will be useful against viral infections of the human eye.
- ribonucleases are members of the ribonuclease A superfamily. Such ribonucleases are pyrimidine-specific endonucleases found in high quantity in the pancreas of certain mammals and of some reptiles. They are involved in endonucleolytic cleavage of 3′-phosphomononucleotides and 3′-phosphooligonucleotides ending in C-P or U-P with 2′,3′-cyclic phosphate intermediates.
- bovine seminal vesicle and brain ribonucleases include bovine seminal vesicle and brain ribonucleases, kidney non-secretory ribonucleases, liver-type ribonucleases, angiogenin; eosinophil cationic protein, pancreatic ribonucleases from different species including human, and bovine pancreatic ribonucleases.
- Ranpirnase which is disclosed in U.S. Pat. No. 5,559,212, and was previously known by the ONCONASE trademark, is a ribonuclease isolated from oocytes of the leopard frog Rana pipiens .
- the amino acid sequence of ranpirnase is provided in SEQ ID NO: 1.
- Ranpirnase has been tested and found to be cytotoxic to cancer cells because of its enzymatic activity against RNA.
- ranpirnase A variant of ranpirnase (hereinafter, the “'805 variant”) is disclosed in U.S. Pat. No. 5,728,805.
- the '805 variant is also a ribonuclease, and has likewise been found to be cytotoxic to certain cancer cells.
- the '805 variant is a close variant of ranpirnase; its amino acid sequence is identical to that of ranpirnase except that it has valine instead of isoleucine at position 11, asparagine instead of aspartic acid at position 20, and arginine instead of serine at position 103 of the ranpirnase amino acid sequence.
- the '805 variant has been referred to as “Val11, Asn20, Arg103-Ranpirnase”.
- the amino acid sequence of the '805 variant is provided in SEQ ID NO:2.
- Amphinase 2 is also a ribonuclease. It is the protein identified as 2325p4 in U.S. Pat. No. 6,239,257 and it too has been found to be cytotoxic to cancer cells.
- the amino acid sequence of Amphinase 2 is provided in SEQ ID NO: 3.
- rArphinase 2 Recombinant Amphinase 2 (“rArphinase 2”) is similar to Amphinase 2, but has a Met residue at position ⁇ 1 and lacks glycan moieties that are located in Amphinase 2 at positions 27 and 91. rAmphinase 2 is described in U.S. Pat. No. 7,229,824. The amino acid sequence of rAmphinase 2 is provided in SEQ ID NO: 4.
- the term “functional equivalent” is intended to mean any protein that differs from any naturally occurring ribonuclease by the deletion, addition or substitution of one or more amino acids, but that retains ribonuclease activity.
- the '805 variant is a functional equivalent of ranpirnase, because it comprises three amino acid substitutions compared to the ranpirnase amino acid sequence, but still has RNase activity.
- a ribonuclease of the RNase A superfamily in particular ranpirnase, can be used in the treatment of a viral infection of the eye.
- a “viral infection of the eye” is a disease which shows symptoms predominantly in the eye of a subject and which is caused by viruses rather than bacteria.
- Viral diseases of the eye include, but are not limited to, conjunctivitis and keratitis, retinitis, keratoconjunctivitis, chorioretinitis, pharyngoconjuctival fever and CMV retinitis.
- Viral conjunctivitis also known as pink eye, is characterized by inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid. Viral conjunctivitis is typically caused by an adenovirus.
- Other viruses that can be responsible for conjunctival infection include herpes simplex virus (HSV), varicella-zoster virus (VZV), enterovirus 70, Coxsackie virus A24, molluscum contagiosum and human immunodeficiency virus (HIV).
- Viral keratitis is an inflammation of the cornea which is predominantly caused by herpes simplex virus.
- Chorioretinitis is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. It is a form of posterior uveitis. Chorioretinitis can be caused by infection with cytomegalovirus (CMV), Varicella-Zoster (HZV), dengue fever, West Nile virus or lymphocytic choriomeningitis virus (LCMV).
- CMV cytomegalovirus
- HZV Varicella-Zoster
- LCMV lymphocytic choriomeningitis virus
- viral infections of the eye can be caused by a virus from the Herpesviridae family of viruses and by an adenovirus selected from the group consisting of 3, 4, 7, 8, 19, 29, and 37.
- Herpesviridae are viruses having a double-stranded, linear DNA genome which are classified in Baltimore class I. Viruses from the Herpesviridae family causing viral infections of the eye include, but are not limited to, type I Herpes simplex virus, human cytomegalovirus and Herpes zoster virus, in particular Herpes zoster ophthalmicus.
- Adenoviridae are double-stranded DNA viruses which are classified in Baltimore class I.
- Adenovirus types 8, 19, 29, and 37 can cause epidemic keratoconjunctivitis
- adenovirus types 3, 4, and 7 can cause pharyngoconjuctival fever types 8, 19, 29, and 37 can cause epidemic keratoconjunctivitis
- Adenovirus types 3, 4, and 7 can cause pharyngoconjuctival fever.
- treating and “treatment,” as used herein, refer to administering to a subject having a viral infection of the eye a therapeutically effective dose of a ribonuclease such as ranpirnase, a ranpirnase variant such as the '805 variant, Arnphinase 2, or rAmphinase 2.
- a ribonuclease such as ranpirnase, a ranpirnase variant such as the '805 variant, Arnphinase 2, or rAmphinase 2.
- the term “treating” covers any treatment of a viral infection of the eye which results in a desired pharmacologic and/or physiologic effect, including arresting disease development, causing regression of the disease, limiting spread of the virus from one cell to another within an individual, limiting replication of a virus in an individual, limiting entry of a virus into the cell of an individual and reducing the number of viruses in an individual or a tissue of this individual.
- terapéuticaally effective dose refers to an amount of a pharmaceutical that results in an improvement or remediation of the symptoms of a disease or condition to be treated.
- a therapeutically effective dose of a ribonuclease such as ranpirnase, '805 variant, Amphinase 2, or rAmphinase 2, delays or minimizes the onset of, or hastens or increases recovery of a subject from, a viral infection of the eye in a subject.
- the RNase may reduce the viral titer in the eye of the infected subject, or may prevent the viral titer in the eye of the infected subject from increasing.
- a therapeutically effective dose of a ribonuclease may provide a therapeutic benefit in the treatment or management of a viral infection of the eye by reducing the spread of the virus from one cell to another and may also prevent disease and/or reduce the severity of symptoms.
- a therapeutically effective dose can be determined by the skilled person as a matter of routine experimentation.
- the therapeutically effective dosage of the pharmaceutical composition can be determined readily by the skilled artisan, for example, from animal studies.
- human clinical studies can be performed to determine the preferred effective dose for humans by a skilled artisan. Such clinical studies are routine and well known in the art.
- the precise dose to be employed will also depend on the route of administration. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal test systems.
- the RNase may be administered to a subject in need thereof in a single dose or in multiple doses.
- the RNase may be administered to the subject until symptoms resolve and/or until the subject is no longer at risk of a virus infection.
- the schedule on which the administration of the RNase (advantageously, ranpirnase) commences, and on which a single dose or multiple doses of the RNase (advantageously, ranpirnase) is or are administered to the subject, and the duration of dosing, can be determined by a person of ordinary skill. These factors may depend on factors such as the severity of symptoms, patient response, etc.
- the administration of a therapeutically effective dose of the RNase may reduce the virus titer in the eye compared to a control that is infected with the virus but not treated with the RNase.
- the administration of a therapeutically effective dose of the RNase may lead to a reduction of the virus titer below the detection level. Determination of virus titers is for example discussed in Reischl (1996) Front Biosci. 1:e 72-7, Application of molecular biology-based methods to the diagnosis of infectious diseases.
- the ribonuclease (advantageously, ranpirnase) is preferably administered topically to the eye, i.e. is administered directly to the eye and not elsewhere on the body.
- the topical administration may be by e.g. eye drops, a suspension, an emulsion, an ointment, a solution, a gel, liposomes, nanoparticles, microemulsions, nanoemulsions, nanosuspensions, niosomes, dendrimers and hydrogels.
- the ribonuclease may be administered by the intravitreal, intracameral, subconjunctival, subtenon, retrobulbar or posterior juxtascleral route.
- the ribonuclease will be a component of a pharmaceutical that includes a vehicle.
- vehicle includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. These agents are generally safe, non-toxic and neither biologically nor otherwise undesirable.
- the vehicle may contain ingredients such as an excipient, a surfactant, an ingredient to adjust the pH of the composition and to buffer within a certain pH range, and a tonicity agent to adjust the tonicity of the composition.
- ingredients such as an excipient, a surfactant, an ingredient to adjust the pH of the composition and to buffer within a certain pH range, and a tonicity agent to adjust the tonicity of the composition.
- Such ingredients are known, and persons of ordinary skill in the art can select such of them as will produce a formulation having appropriate characteristics when combined with the RNase (advantageously, ranpirnase).
- a substance here, a ribonuclease
- Draize test uses the Globally Harmonized System of Classification Evaluation Criteria and using the European Economic Community Ocular Evaluation Criteria.
- the criteria evaluated are corneal opacity, iris lesion, conjunctival redness and conjunctival edema. If the score for each of these criteria is zero, the tested substance is considered non-irritating to the eye.
- 1 and 4 show, respectively, the scale used for scoring ocular lesions observed in a rabbit that has undergone a Draize test and the European Economic Community Ocular Evaluation Criteria used to classify the ocular irritation caused by a test article in a Draize test.
- ranpirnase As stated above, before the present invention, no person of ordinary skill in the art would administer to the eye ranpirnase or any of the other three above-identified proteinaceous enzymatically active ribonucleases. However, such administration of ranpirnase has been modeled using the Draize test and the results of this experiment demonstrate that ranpirnase is non-irritating as defined by two accepted standards.
- a 0.1% mL solution made up of 0.1% ranpirnase in a proprietary aqueous solution used as a vehicle was used as a test article.
- the total ocular irritation scores for the examinations at 24, 48, and 72 hours were individually added for corneal opacity, iris lesion, conjunctival redness, and conjunctival edema and the mean scores for these scoring parameters were compared to the European Economic Community Ocular Evaluation Criteria. Because all these scores (and therefore the calculated mean scores) were zero, the test subject was considered to be non-irritating as defined by the European Economic Community Ocular Evaluation Criteria.
- the 24-, 48-, and 72-hour scores were added separately for each animal and each total divided by 3 (three time points) to yield the individual mean scores for each animal. Because all these scores (and therefore the calculated quotients) were zero, the test subject was considered to be non-irritating as defined by the Globally Harmonized System of Classification Evaluation Criteria.
- ranpirnase delivered to the eye in an aqueous solution is non-irritating as defined by the Globally Harmonized System of Classification Evaluation Criteria and by the European Economic Community Ocular Evaluation Criteria, even though ranpirnase is a protein (which would be expected to be irritating to the eye).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- The invention relates to viral infections of the eye, and more particularly relates to methods and pharmaceuticals for treatment of viral infections of the eye. In its most immediate sense, the invention relates to treatment of human eye infections caused by Herpesviridae viruses (including but not limited to Human cytomegalovirus, herpes zoster virus, and varicella zoster virus) and Adenoviridae viruses.
- Viral diseases of the eye can have significant consequences.
Type 1 herpes simplex virus can cause conjunctivitis and keratitis, Human cytomegalovirus can cause retinitis, adenovirus types 8, 19, 29, and 37 can cause epidemic keratoconjunctivitis, andadenovirus types - Human cytomegalovirus (CMV) is another member of the Herpesviridae family. At least 60% of the US population has been exposed to CMV, with a prevalence of more than 90% in high-risk groups (e.g., unborn babies whose mothers become infected with CMV during pregnancy, people with HIV, and transplant recipients).
- CMV retinitis is one of the most common opportunistic infections in persons with AIDS or pharmacologically induced immunosuppression. Individuals with CMV retinitis typically exhibit a progressive decrease in visual acuity, which may progress to blindness. Long-term CMV treatment is necessary to prevent retinitis relapse.
- Immune reconstitution syndrome (IRIS) is reported in 16%-63% of HIV-infected patients with CMV retinitis following the initiation of HAART (Highly Active Antiretroviral Treatment). CMV IRIS may manifest as painless floaters, blurred vision, photopia, decreased visual acuity, or ocular pain. Some patients may develop macular edema leading to vision loss or proliferative vitreoretinopathy, spontaneous vitreal hemorrhage, and retinal detachment.
- It is known to treat viral eye infections with acyclovir but such treatment is not entirely satisfactory. Topical acyclovir must be applied frequently and causes irritation of the eye. Oral acyclovir causes significant adverse side effects. Other antiviral medications such as gancyclovir, valacyclovir and valgancyclovir are used to treat viral eye infections, and such treatments are also not entirely satisfactory. Gancyclovir is administered intravenously, and therefore cannot be used outside e.g. a hospital setting. Oral antiviral medications such as valacyclovir and valgancyclovir have disadvantages; they are known to cause fever, rash, diarrhea, and hematologic effects (e.g., neutropenia, anemia, thrombocytopenia). In some cases neutropenia may respond to lowering the dose or using drugs that stimulate the production of neutrophils by the bone marrow as granulocyte colony-stimulating factor [G-CSF], or granulocyte-macrophage colony-stimulating factor [GM-CSF]. These toxic effects can be difficult to manage.
- It would therefore be advantageous to provide a better method and a better pharmaceutical for treating viral eye infections in humans.
- Various enzymatically active ribonucleases, including ranpirnase and other proteins that are highly homologous to it, are known to have antiviral activity, and to have activity against viruses in the Herpesviridae family (specifically including but not limited to Herpes
simplex virus types type 2 adenovirus. However, proteins are known to be highly irritating to the eye due to an intense inflammatory response mediated by T-cells. For this reason, although ranpirnase and other related proteins have been investigated for use against various viral infections, they have not been investigated for use against viral infections of the eye. - Despite the expectation that proteinaceous ranpirnase would cause irritation in the eye, irritation of topically applied ranpirnase in the eye was studied in a rabbit model. In this experiment, ranpirnase was demonstrated to be non-irritating as determined using the Globally Harmonized System of Classification Evaluation Criteria and the European Economic Community Ocular Evaluation Criteria. This was a remarkable result, because administration of a foreign protein to the eye can produce corneal irritation. As a result, ranpirnase and other proteins that are highly homologous to it are expected to be useful in treating viral infections of the human eye.
- The invention will be better understood with reference to the following exemplary and non-limiting drawings, in which:
-
FIG. 1 shows the scale used for scoring ocular lesions observed in a rabbit that has undergone a Draize test; -
FIG. 2 shows the results of a Draize test in which a ranpirnase solution was applied to the right eye of three rabbits; -
FIG. 3 shows the results of the Draize test ofFIG. 2 in which the left eye of each of the rabbits was untreated; and -
FIG. 4 shows the European Economic Community Ocular Evaluation Criteria used to classify the ocular irritation caused by a test article in a Draize test. - Ranpirnase is a proteinaceous enzymatically active ribonuclease (the word “ribonuclease” is frequently abbreviated as “RNase”) that is disclosed and claimed in U.S. Pat. No. 5,559,212. U.S. Pat. Nos. 5,728,805, 6,239,257, 7,229,824 and 8,518,399 disclose three other proteinaceous enzymatically active ribonucleases that are highly homologous to ranpirnase:
-
- a) the ribonuclease of SEQ ID NO:2 in U.S. Pat. No. 5,728,805, herein referred to as the “'805 variant”;
- b) the ribonuclease of SEQ ID NO:2 in U.S. Pat. No. 6,239,257, herein referred to as “Amphinase 2”, and;
- c) the ribonuclease of SEQ ID NO:59 of U.S. Pat. No. 7,229,824, herein referred to as “
rAmphinase 2”.
- U.S. Pat. No. 8,518,399 discloses that ranpirnase, the '805 variant, and rAmphinase 2 have antiviral activity against Herpesviridae viruses, specifically including but not limited to
Herpes simplex types - Commonly-owned copending patent application Ser. No. 14/736,170 filed Jun. 10, 2015 and published as US 2015/0376584 A1 discloses that ranpirnase has antiviral activity against a number of viruses, including
type 2 adenovirus. As stated therein, the viruses in the Adenoviridae family are very closely related and the demonstrated antiviral activity of ranpirnase against any one virus within the Adenoviridae family is strong evidence that ranpirnase will have the same anti-replication activity against all viruses within the Adenoviridae family. Furthermore, as stated in that pending patent application, to a person of ordinary skill in this art, the similarities of homology and activity of these three other ribonucleases is strong evidence that these three other ribonucleases will have the same activity as ranpirnase has. Hence, although in vitro experiments have not yet been repeated using the '805 variant, Amphinase 2, or rAmphinase 2, a person of ordinary skill in this art would conclude that these three ribonucleases will likewise be active against all the viruses in the Adenoviridae family. - Thus, ranpirnase, the '805 variant, Amphinase 2, and rAmphinase 2 have either been demonstrated to be active against
type 1 Herpes simplex virus and viruses in the Adenoviridae family or would be expected to be so active. For this reason, a person of ordinary skill in the art would expect that all four of these proteinaceous enzymatically active ribonucleases will be useful against viral infections of the human eye. - All four of these ribonucleases are members of the ribonuclease A superfamily. Such ribonucleases are pyrimidine-specific endonucleases found in high quantity in the pancreas of certain mammals and of some reptiles. They are involved in endonucleolytic cleavage of 3′-phosphomononucleotides and 3′-phosphooligonucleotides ending in C-P or U-P with 2′,3′-cyclic phosphate intermediates. Other members of this superfamily include bovine seminal vesicle and brain ribonucleases, kidney non-secretory ribonucleases, liver-type ribonucleases, angiogenin; eosinophil cationic protein, pancreatic ribonucleases from different species including human, and bovine pancreatic ribonucleases.
- Ranpirnase, which is disclosed in U.S. Pat. No. 5,559,212, and was previously known by the ONCONASE trademark, is a ribonuclease isolated from oocytes of the leopard frog Rana pipiens. The amino acid sequence of ranpirnase is provided in SEQ ID NO: 1. Ranpirnase has been tested and found to be cytotoxic to cancer cells because of its enzymatic activity against RNA.
- A variant of ranpirnase (hereinafter, the “'805 variant”) is disclosed in U.S. Pat. No. 5,728,805. The '805 variant is also a ribonuclease, and has likewise been found to be cytotoxic to certain cancer cells. The '805 variant is a close variant of ranpirnase; its amino acid sequence is identical to that of ranpirnase except that it has valine instead of isoleucine at position 11, asparagine instead of aspartic acid at
position 20, and arginine instead of serine at position 103 of the ranpirnase amino acid sequence. The '805 variant has been referred to as “Val11, Asn20, Arg103-Ranpirnase”. The amino acid sequence of the '805 variant is provided in SEQ ID NO:2. -
Amphinase 2 is also a ribonuclease. It is the protein identified as 2325p4 in U.S. Pat. No. 6,239,257 and it too has been found to be cytotoxic to cancer cells. The amino acid sequence ofAmphinase 2 is provided in SEQ ID NO: 3. - Recombinant Amphinase 2 (“
rArphinase 2”) is similar toAmphinase 2, but has a Met residue at position −1 and lacks glycan moieties that are located inAmphinase 2 at positions 27 and 91.rAmphinase 2 is described in U.S. Pat. No. 7,229,824. The amino acid sequence ofrAmphinase 2 is provided in SEQ ID NO: 4. - The term “functional equivalent” is intended to mean any protein that differs from any naturally occurring ribonuclease by the deletion, addition or substitution of one or more amino acids, but that retains ribonuclease activity. For example, the '805 variant is a functional equivalent of ranpirnase, because it comprises three amino acid substitutions compared to the ranpirnase amino acid sequence, but still has RNase activity.
- The disclosures of U.S. Pat. Nos. 5,559,212, 5,728,805, 6,239,257, 7,229,824, 8,518,399, 8,663,964 and published patent application US 2015/0376584 A1 are all incorporated by reference herein in their entireties for all purposes.
- As discussed above, it has been found that a ribonuclease of the RNase A superfamily, in particular ranpirnase, can be used in the treatment of a viral infection of the eye. A “viral infection of the eye” is a disease which shows symptoms predominantly in the eye of a subject and which is caused by viruses rather than bacteria. Viral diseases of the eye include, but are not limited to, conjunctivitis and keratitis, retinitis, keratoconjunctivitis, chorioretinitis, pharyngoconjuctival fever and CMV retinitis.
- Viral conjunctivitis, also known as pink eye, is characterized by inflammation of the outermost layer of the white part of the eye and the inner surface of the eyelid. Viral conjunctivitis is typically caused by an adenovirus. Other viruses that can be responsible for conjunctival infection include herpes simplex virus (HSV), varicella-zoster virus (VZV), enterovirus 70, Coxsackie virus A24, molluscum contagiosum and human immunodeficiency virus (HIV).
- Viral keratitis is an inflammation of the cornea which is predominantly caused by herpes simplex virus.
- Chorioretinitis is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. It is a form of posterior uveitis. Chorioretinitis can be caused by infection with cytomegalovirus (CMV), Varicella-Zoster (HZV), dengue fever, West Nile virus or lymphocytic choriomeningitis virus (LCMV).
- In particular, viral infections of the eye can be caused by a virus from the Herpesviridae family of viruses and by an adenovirus selected from the group consisting of 3, 4, 7, 8, 19, 29, and 37.
- Herpesviridae are viruses having a double-stranded, linear DNA genome which are classified in Baltimore class I. Viruses from the Herpesviridae family causing viral infections of the eye include, but are not limited to, type I Herpes simplex virus, human cytomegalovirus and Herpes zoster virus, in particular Herpes zoster ophthalmicus.
- Adenoviridae are double-stranded DNA viruses which are classified in Baltimore class I. Adenovirus types 8, 19, 29, and 37 can cause epidemic keratoconjunctivitis, and
adenovirus types Adenovirus types - The terms “treating” and “treatment,” as used herein, refer to administering to a subject having a viral infection of the eye a therapeutically effective dose of a ribonuclease such as ranpirnase, a ranpirnase variant such as the '805 variant,
Arnphinase 2, orrAmphinase 2. As used herein, the term “treating” covers any treatment of a viral infection of the eye which results in a desired pharmacologic and/or physiologic effect, including arresting disease development, causing regression of the disease, limiting spread of the virus from one cell to another within an individual, limiting replication of a virus in an individual, limiting entry of a virus into the cell of an individual and reducing the number of viruses in an individual or a tissue of this individual. - The term “therapeutically effective dose” refers to an amount of a pharmaceutical that results in an improvement or remediation of the symptoms of a disease or condition to be treated. A therapeutically effective dose of a ribonuclease such as ranpirnase, '805 variant,
Amphinase 2, orrAmphinase 2, delays or minimizes the onset of, or hastens or increases recovery of a subject from, a viral infection of the eye in a subject. The RNase may reduce the viral titer in the eye of the infected subject, or may prevent the viral titer in the eye of the infected subject from increasing. A therapeutically effective dose of a ribonuclease may provide a therapeutic benefit in the treatment or management of a viral infection of the eye by reducing the spread of the virus from one cell to another and may also prevent disease and/or reduce the severity of symptoms. - A therapeutically effective dose can be determined by the skilled person as a matter of routine experimentation. The therapeutically effective dosage of the pharmaceutical composition can be determined readily by the skilled artisan, for example, from animal studies. In addition, human clinical studies can be performed to determine the preferred effective dose for humans by a skilled artisan. Such clinical studies are routine and well known in the art. The precise dose to be employed will also depend on the route of administration. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal test systems.
- The RNase may be administered to a subject in need thereof in a single dose or in multiple doses. The RNase may be administered to the subject until symptoms resolve and/or until the subject is no longer at risk of a virus infection. The schedule on which the administration of the RNase (advantageously, ranpirnase) commences, and on which a single dose or multiple doses of the RNase (advantageously, ranpirnase) is or are administered to the subject, and the duration of dosing, can be determined by a person of ordinary skill. These factors may depend on factors such as the severity of symptoms, patient response, etc.
- The administration of a therapeutically effective dose of the RNase (advantageously, ranpirnase) may reduce the virus titer in the eye compared to a control that is infected with the virus but not treated with the RNase.
- The administration of a therapeutically effective dose of the RNase (advantageously, ranpirnase) may lead to a reduction of the virus titer below the detection level. Determination of virus titers is for example discussed in Reischl (1996) Front Biosci. 1:e 72-7, Application of molecular biology-based methods to the diagnosis of infectious diseases.
- The ribonuclease (advantageously, ranpirnase) is preferably administered topically to the eye, i.e. is administered directly to the eye and not elsewhere on the body. The topical administration may be by e.g. eye drops, a suspension, an emulsion, an ointment, a solution, a gel, liposomes, nanoparticles, microemulsions, nanoemulsions, nanosuspensions, niosomes, dendrimers and hydrogels. Alternatively, the ribonuclease (advantageously, ranpirnase) may be administered by the intravitreal, intracameral, subconjunctival, subtenon, retrobulbar or posterior juxtascleral route.
- The ribonuclease will be a component of a pharmaceutical that includes a vehicle. The term “vehicle” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. These agents are generally safe, non-toxic and neither biologically nor otherwise undesirable.
- The vehicle may contain ingredients such as an excipient, a surfactant, an ingredient to adjust the pH of the composition and to buffer within a certain pH range, and a tonicity agent to adjust the tonicity of the composition. Such ingredients are known, and persons of ordinary skill in the art can select such of them as will produce a formulation having appropriate characteristics when combined with the RNase (advantageously, ranpirnase).
- It is possible to determine whether a substance (here, a ribonuclease) is non-irritating to the eye in a Draize test using the Globally Harmonized System of Classification Evaluation Criteria and using the European Economic Community Ocular Evaluation Criteria. In the Draize test the RNase is placed in the conjunctival sac of a rabbit's eye and the eye is examined at 1, 24, 48 and 72 hours after instillation of ranpirnase. The criteria evaluated are corneal opacity, iris lesion, conjunctival redness and conjunctival edema. If the score for each of these criteria is zero, the tested substance is considered non-irritating to the eye.
FIGS. 1 and 4 show, respectively, the scale used for scoring ocular lesions observed in a rabbit that has undergone a Draize test and the European Economic Community Ocular Evaluation Criteria used to classify the ocular irritation caused by a test article in a Draize test. - As stated above, before the present invention, no person of ordinary skill in the art would administer to the eye ranpirnase or any of the other three above-identified proteinaceous enzymatically active ribonucleases. However, such administration of ranpirnase has been modeled using the Draize test and the results of this experiment demonstrate that ranpirnase is non-irritating as defined by two accepted standards.
- A 0.1% mL solution made up of 0.1% ranpirnase in a proprietary aqueous solution used as a vehicle was used as a test article. Three rabbits were used; each was a male New Zealand White rabbit that was approximately 16 weeks old at the time of the experiment and that weighed 3.3 to 3.4 kg.
- After administration of two drops of Tetracaine pre-anesthetic to the corneal surface of both eyes of each rabbit, the test article was placed in the conjunctival sac of the right eye of each rabbit by gently pulling the lower lid away from the eyeball; the lids were gently held together for approximately one second to limit the loss of the test material. The left eye of each rabbit remained untreated and served as the control. The eyes of the animals were examined at 1 (+15 minutes), 24, 48, and 72 hours (±1 hour) after installation of the test article. The grades of ocular reaction according to Draize (
FIG. 1 ) were manually recorded at each examination (FIGS. 2 and 3 ). As can be seen inFIG. 2 , there was an ocular reaction in each animal one hour post-instillation of the test article but in every instance that reaction was completely resolved by 24 hours and thereafter. - To determine the degree of irritation caused by the test article using the European Economic Community Ocular Evaluation Criteria (
FIG. 4 ), the total ocular irritation scores for the examinations at 24, 48, and 72 hours were individually added for corneal opacity, iris lesion, conjunctival redness, and conjunctival edema and the mean scores for these scoring parameters were compared to the European Economic Community Ocular Evaluation Criteria. Because all these scores (and therefore the calculated mean scores) were zero, the test subject was considered to be non-irritating as defined by the European Economic Community Ocular Evaluation Criteria. - To determine the degree of irritation caused by the test article using the Globally Harmonized System of Classification Evaluation Criteria, the 24-, 48-, and 72-hour scores were added separately for each animal and each total divided by 3 (three time points) to yield the individual mean scores for each animal. Because all these scores (and therefore the calculated quotients) were zero, the test subject was considered to be non-irritating as defined by the Globally Harmonized System of Classification Evaluation Criteria.
- Hence, these test data demonstrate a new and unexpected result: ranpirnase delivered to the eye in an aqueous solution is non-irritating as defined by the Globally Harmonized System of Classification Evaluation Criteria and by the European Economic Community Ocular Evaluation Criteria, even though ranpirnase is a protein (which would be expected to be irritating to the eye).
- Although this experiment was carried out using a solution of ranpirnase in a proprietary aqueous vehicle, a person of ordinary skill in the art would consider it likely that solutions of the three above-identified proteinaceous enzymatically active ribonucleases would behave in the same way because of their similarities to ranpirnase in respect of activity and homology.
- Although at least one preferred embodiment of the invention has been described above, this description is not limiting and is only exemplary. The scope of the invention is defined only by the claims, which follow:
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/368,330 US20190216904A1 (en) | 2015-06-15 | 2019-03-28 | Methods and pharmaceuticals for treatment of viral infections of the eye |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562175961P | 2015-06-15 | 2015-06-15 | |
US15/180,270 US10293032B2 (en) | 2015-06-15 | 2016-06-13 | Methods and pharmaceuticals for treatment of viral infections of the eye |
US16/368,330 US20190216904A1 (en) | 2015-06-15 | 2019-03-28 | Methods and pharmaceuticals for treatment of viral infections of the eye |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/180,270 Continuation US10293032B2 (en) | 2015-06-15 | 2016-06-13 | Methods and pharmaceuticals for treatment of viral infections of the eye |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190216904A1 true US20190216904A1 (en) | 2019-07-18 |
Family
ID=56194615
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/180,270 Active 2036-07-26 US10293032B2 (en) | 2015-06-15 | 2016-06-13 | Methods and pharmaceuticals for treatment of viral infections of the eye |
US16/368,330 Pending US20190216904A1 (en) | 2015-06-15 | 2019-03-28 | Methods and pharmaceuticals for treatment of viral infections of the eye |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/180,270 Active 2036-07-26 US10293032B2 (en) | 2015-06-15 | 2016-06-13 | Methods and pharmaceuticals for treatment of viral infections of the eye |
Country Status (12)
Country | Link |
---|---|
US (2) | US10293032B2 (en) |
EP (1) | EP3307238A1 (en) |
JP (1) | JP6862366B2 (en) |
KR (1) | KR20180026455A (en) |
CN (2) | CN117159694A (en) |
AU (2) | AU2016277827B2 (en) |
CA (1) | CA2989611C (en) |
IL (1) | IL256327B (en) |
MX (1) | MX2017016368A (en) |
RU (1) | RU2739392C2 (en) |
SG (1) | SG10201911292SA (en) |
WO (1) | WO2016205109A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
WO2021188866A1 (en) * | 2020-03-20 | 2021-09-23 | Orgenesis Inc. | Ribonucleases for treating viral infections |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9919034B2 (en) | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
JP6862366B2 (en) | 2015-06-15 | 2021-04-21 | タミール バイオテクノロジー,インコーポレイテッド | Drugs for the treatment of viral infections of the eye |
CA2999514A1 (en) * | 2015-09-25 | 2017-03-30 | Okogen, Inc. | Viral conjunctivitis treatment using ranpirnase and/or amphinase |
CN114269344A (en) * | 2019-06-25 | 2022-04-01 | 微生物公司 | Compositions and methods for treating or preventing ocular infections with felodivir |
AU2021259787A1 (en) * | 2020-04-23 | 2022-12-22 | Okogen, Inc. | Treatment of viral conjunctivitis |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4882421A (en) | 1982-09-23 | 1989-11-21 | Alfacell Corporation | Pharmaceutical for treating tumors and method for making it |
US5559212A (en) | 1988-04-06 | 1996-09-24 | Alfacell Corporation | Frog embryo and egg-derived tumor cell anti-proliferation protein |
US5728805A (en) | 1988-04-06 | 1998-03-17 | Alfacell Corp. | Pharmaceuticals and method for making them |
US5840840A (en) | 1990-04-17 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Selective RNase cytotoxic reagents |
IL100881A (en) | 1992-02-06 | 1996-06-18 | Porat Michael | Prophylactic lubricating composition and devices and method for using same |
DE69731463T2 (en) | 1996-02-21 | 2005-10-27 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | RECOMBINANT RIBONUCLEASE PROTEINS |
US6649392B1 (en) | 1996-04-04 | 2003-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods |
US6239257B1 (en) | 1998-12-30 | 2001-05-29 | Alfacell Corporation | Family of proteins belonging to the pancreatic ribonuclease a superfamily |
US20030099629A1 (en) | 1999-03-11 | 2003-05-29 | Immunomedics, Inc. | Recombinant onconase and chemical conjugates and fusion proteins of recombinant onconase |
US6175003B1 (en) | 1999-09-10 | 2001-01-16 | Alfacell Corporation | Nucleic acids encoding ribonucleases and methods of making them |
US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
US20040126865A1 (en) | 2002-12-30 | 2004-07-01 | Alfacell Corporation | Nucleic acids encoding ranpirnase variants and methods of making them |
US7229824B2 (en) | 2003-07-17 | 2007-06-12 | Alfacell Corporation | Ribonucleases and methods of making them recombinantly |
CA2555661C (en) * | 2004-02-13 | 2017-11-21 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic rnases |
US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US20080161324A1 (en) | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
DE102007032507A1 (en) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | pyridazinone derivatives |
US20090202513A1 (en) | 2008-01-07 | 2009-08-13 | The University Of Vermont And State Agriculture College | Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer |
CN107574156A (en) | 2008-11-26 | 2018-01-12 | 美国国有健康与人类服务部 | Virus like particle compositions and its application method |
CN102711745A (en) | 2009-12-01 | 2012-10-03 | 谢普科斯生物技术有限公司 | Topical use of hydroxytyrosol and derivatives for the prevention of HIV infection |
US8518399B2 (en) * | 2010-11-17 | 2013-08-27 | Tamir Biotechnology, Inc. | Methods of treating infections originating from viruses in the herpesviridae family |
US8663964B2 (en) | 2011-07-20 | 2014-03-04 | Tamir Biotechnology, Inc. | Methods of treating human papillomavirus |
WO2013039857A1 (en) * | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) * | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK2790722T3 (en) | 2011-12-12 | 2019-03-25 | The Board Of Trustees Of The Univ Of Illionis | COMPOSITION AND METHOD OF TREATING NUCLEAR ACID-RELATED EYE DISEASE |
MX2016012536A (en) | 2014-03-28 | 2017-04-06 | Tamir Biotechnology Inc | Onconase for use in treating or preventing viral infections. |
US9919034B2 (en) | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
US20170157219A1 (en) | 2014-03-28 | 2017-06-08 | Tamir Biotechnology, Inc. | Methods of treating zika virus, mers-cov, chikungunya, venezuelan equine encephalitus, and rhinovirus in mammalian patients |
US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
US9642794B2 (en) | 2014-08-18 | 2017-05-09 | Tamir Biotechnology, Inc. | Antiviral pharmaceutical for topical administration |
US20160045574A1 (en) | 2014-08-18 | 2016-02-18 | Tamir Biotechnology, Inc. | Antiviral pharmaceutical for topical administration |
JP6862366B2 (en) | 2015-06-15 | 2021-04-21 | タミール バイオテクノロジー,インコーポレイテッド | Drugs for the treatment of viral infections of the eye |
WO2017142807A1 (en) | 2016-02-16 | 2017-08-24 | Tamir Biotechnology, Inc. | Treatment or prevention of zika virus infections by administration of a ribonuclease |
-
2016
- 2016-06-13 JP JP2017565828A patent/JP6862366B2/en active Active
- 2016-06-13 RU RU2018101139A patent/RU2739392C2/en active
- 2016-06-13 CA CA2989611A patent/CA2989611C/en active Active
- 2016-06-13 KR KR1020187001163A patent/KR20180026455A/en not_active Application Discontinuation
- 2016-06-13 EP EP16731753.6A patent/EP3307238A1/en active Pending
- 2016-06-13 CN CN202311093748.6A patent/CN117159694A/en active Pending
- 2016-06-13 WO PCT/US2016/037174 patent/WO2016205109A1/en active Application Filing
- 2016-06-13 US US15/180,270 patent/US10293032B2/en active Active
- 2016-06-13 AU AU2016277827A patent/AU2016277827B2/en active Active
- 2016-06-13 SG SG10201911292SA patent/SG10201911292SA/en unknown
- 2016-06-13 CN CN201680047370.8A patent/CN107920990A/en active Pending
- 2016-06-13 MX MX2017016368A patent/MX2017016368A/en unknown
-
2017
- 2017-12-14 IL IL256327A patent/IL256327B/en active IP Right Grant
-
2019
- 2019-03-28 US US16/368,330 patent/US20190216904A1/en active Pending
-
2021
- 2021-06-30 AU AU2021204520A patent/AU2021204520B2/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
WO2021188866A1 (en) * | 2020-03-20 | 2021-09-23 | Orgenesis Inc. | Ribonucleases for treating viral infections |
Also Published As
Publication number | Publication date |
---|---|
US20160361392A1 (en) | 2016-12-15 |
AU2016277827B2 (en) | 2021-04-29 |
KR20180026455A (en) | 2018-03-12 |
EP3307238A1 (en) | 2018-04-18 |
JP6862366B2 (en) | 2021-04-21 |
JP2018517423A (en) | 2018-07-05 |
RU2018101139A (en) | 2019-07-15 |
SG10201911292SA (en) | 2020-02-27 |
AU2021204520A1 (en) | 2021-07-29 |
CA2989611C (en) | 2024-02-27 |
RU2739392C2 (en) | 2020-12-23 |
IL256327A (en) | 2018-02-28 |
IL256327B (en) | 2020-01-30 |
MX2017016368A (en) | 2018-04-24 |
CA2989611A1 (en) | 2016-12-22 |
RU2018101139A3 (en) | 2019-12-06 |
CN117159694A (en) | 2023-12-05 |
CN107920990A (en) | 2018-04-17 |
US10293032B2 (en) | 2019-05-21 |
AU2021204520B2 (en) | 2023-05-11 |
WO2016205109A1 (en) | 2016-12-22 |
AU2016277827A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10293032B2 (en) | Methods and pharmaceuticals for treatment of viral infections of the eye | |
EP3347034B1 (en) | A hepatocyte growth factor receptor (hgfr)-binding composition for use in a method of treating corneal haze or scarring | |
US10010586B2 (en) | Method of treating intraocular tissue pathologies with nerve growth factor | |
US20220265783A1 (en) | Viral conjunctivitis treatment using ranpirnase and/or amphinase | |
Cheng et al. | Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation | |
WO2022173923A1 (en) | Methods for ophthalmic delivery of roflumilast | |
JPH06271478A (en) | Agent for treating dry eye | |
JP2000510449A (en) | Gene therapy for proliferative vitreoretinopathy | |
US20200376019A1 (en) | miR29 MIMICS FOR THE TREATMENT OF OCULAR FIBROSIS | |
NO328085B1 (en) | Use of staurosporine derivatives for the manufacture of a drug for the treatment of ocular neovascular diseases | |
Moore | Cornea and sclera | |
JPH0881389A (en) | Agent for multiplying pigment epithelial cell of retina | |
US8106096B2 (en) | Compositions and methods for treatment of optic nerve diseases | |
TW202021968A (en) | Methods and compositions for drugs to treat ophthalmic diseases | |
CN114099515A (en) | Application of methotrexate in preparation of medicine for treating retinitis pigmentosa | |
KR20140046781A (en) | Composition for preventing or treating of choroidal neovascularization including complement factor h | |
RU2161940C2 (en) | Method for treating the cases of keratoleukoma after viral keratitis occurred | |
Se Kwon | Reactivation of latent herpes simplex virus and chemotherapy of herpes infection | |
RU2068691C1 (en) | Agent for treatment of viral diseases caused by herpes virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TAMIR BIOTECHNOLOGY, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SQUIQUERA, LUIS;REEL/FRAME:050445/0234 Effective date: 20160627 Owner name: TAMIR BIOTECHNOLOGY, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SULLEY, JAMIE;REEL/FRAME:050445/0255 Effective date: 20170216 |
|
AS | Assignment |
Owner name: ORGENESIS INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAMIR BIOTECHNOLOGY, INC.;REEL/FRAME:052892/0702 Effective date: 20200417 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |